Haydeh Payami

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1956997/publications.pdf

Version: 2024-02-01

71 papers	9,571 citations	76326 40 h-index	79698 73 g-index
79 all docs	79 docs citations	79 times ranked	12482 citing authors

#	Article	IF	Citations
1	Large-scale association analyses identify host factors influencing human gut microbiome composition. Nature Genetics, 2021, 53, 156-165.	21.4	676
2	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	5.3	30
3	Exploring human-genome gut-microbiome interaction in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 74.	5.3	15
4	Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. Npj Parkinson's Disease, 2020, 6, 11.	5.3	140
5	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
6	Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. Movement Disorders, 2018, 33, 793-804.	3.9	130
7	Functional variants in the LRRK2 gene confer shared effects on risk for Crohnâ€™s disease and Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	273
8	Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease. Neurology: Genetics, 2018, 4, e271.	1.9	12
9	Caffeine, creatine, GRIN2A and Parkinson's disease progression. Journal of the Neurological Sciences, 2017, 375, 355-359.	0.6	23
10	Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Movement Disorders, 2017, 32, 739-749.	3.9	649
11	The emerging science of precision medicine and pharmacogenomics for Parkinson's disease. Movement Disorders, 2017, 32, 1139-1146.	3.9	42
12	DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurology: Genetics, 2016, 2, e72.	1.9	11
13	Identification of genetic modifiers of age-at-onset for familial Parkinsonâ€™s disease. Human Molecular Genetics, 2016, 25, 3849-3862.	2.9	44
14	The relationship between obsessiveâ€compulsive symptoms and PARKIN genotype: The COREâ€PD study. Movement Disorders, 2015, 30, 278-283.	3.9	16
15	Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson Disease. PLoS Genetics, 2014, 10, e1004774.	3.5	7
16	Cognitive and Motor Function in Long-DurationPARKIN-Associated Parkinson Disease. JAMA Neurology, 2014, 71, 62.	9.0	49
17	Identification of a novel Parkinsonâ€™s disease locus via stratified genome-wide association study. BMC Genomics, 2014, 15, 118.	2.8	53
18	Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson's Disease. A Perspective. Neurotherapeutics, 2014, 11, 111-116.	4.4	14

#	Article	IF	Citations
19	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	21.4	1,685
20	Association of Parkinson Disease with Structural and Regulatory Variants in the HLA Region. American Journal of Human Genetics, 2013, 93, 984-993.	6.2	145
21	Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. PLoS Genetics, 2012, 8, e1002548.	3.5	495
22	Metaâ€analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Annals of Neurology, 2012, 71, 370-384.	5.3	264
23	Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee. PLoS Genetics, 2011, 7, e1002237.	3.5	206
24	Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region. PLoS ONE, 2011, 6, e27109.	2.5	60
25	Diseaseâ€related and genetic correlates of psychotic symptoms in Parkinson's disease. Movement Disorders, 2011, 26, 2190-2195.	3.9	61
26	Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 564-568.	1.9	90
27	Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease. Genetic Epidemiology, 2010, 34, 92-99.	1.3	6
28	Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Movement Disorders, 2010, 25, 2156-2163.	3.9	108
29	Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nature Genetics, 2010, 42, 781-785.	21.4	692
30	SNCA Variant Associated With Parkinson Disease and Plasma Î±-Synuclein Level. Archives of Neurology, 2010, 67, 1350-6.	4.5	157
31	The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. Journal of Human Genetics, 2010, 55, 241-243.	2.3	70
32	Lack of evidence for an association between UCHL1 S18Y and Parkinsonâ€™s disease. European Journal of Neurology, 2008, 15, 134-139.	3.3	25
33	Exploring gene-environment interactions in Parkinsonâ€™s disease. Human Genetics, 2008, 123, 257-265.	3.8	92
34	Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Movement Disorders, 2008, 23, 88-95.	3.9	129
35	Genetic association between Î±â€synuclein and idiopathic parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1222-1230.	1.7	60
36	Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Annals of Neurology, 2007, 61, 47-54.	5.3	105

#	Article	IF	Citations
37	DBH â^'1021Câ†'T does not modify risk or age at onset in Parkinson's disease. Annals of Neurology, 2007, 62, 99-101.	5.3	7
38	Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Annals of Neurology, 2007, 62, 137-144.	5.3	129
39	Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinsonâ€™s disease. Neurogenetics, 2007, 8, 95-102.	1.4	34
40	Validity and Utility of a LRRK2 G2019S Mutation Test for the Diagnosis of Parkinson's Disease. Genetic Testing and Molecular Biomarkers, 2006, 10, 221-227.	1.7	32
41	LRRK2 G2019S in Families with Parkinson Disease Who Originated from Europe and the Middle East: Evidence of Two Distinct Founding Events Beginning Two Millennia Ago. American Journal of Human Genetics, 2006, 79, 752-758.	6.2	111
42	Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurology, The, 2006, 5, 917-923.	10.2	83
43	Parkinson's disease andLRRK2: Frequency of a common mutation in U.S. movement disorder clinics. Movement Disorders, 2006, 21, 519-523.	3.9	84
44	Early-Onset Alzheimer Disease in Families With Late-Onset Alzheimer Disease. Archives of Neurology, 2006, 63, 1307.	4.5	62
45	Analysis of the LRRK2 G2019S Mutation in Alzheimer Disease. Archives of Neurology, 2006, 63, 156.	4.5	21
46	parkinmutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism. BMC Neurology, 2005, 5, 4.	1.8	10
47	False-positive SCA8 gene test in a patient with pathologically proven multiple system atrophy. Annals of Neurology, 2005, 57, 462-463.	5.3	29
48	One step closer to fixing association studies: evidence for age- and gender-specific allele frequency variations and deviations from Hardy-Weinberg expectations in controls. Human Genetics, 2005, 118, 322-330.	3.8	25
49	Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations. American Journal of Human Genetics, 2005, 76, 672-680.	6.2	524
50	Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease. Neurogenetics, 2004, 5, 121-128.	1.4	27
51	parkin mutation analysis in clinic patients with early-onset Parkinson's disease. American Journal of Medical Genetics Part A, 2004, 129A, 44-50.	2.4	49
52	Evidence for a Novel Late-Onset Alzheimer Disease Locus on Chromosome 19p13.2. American Journal of Human Genetics, 2004, 75, 398-409.	6.2	90
53	A linkage study of candidate loci in familial Parkinson's Disease. BMC Neurology, 2003, 3, 6.	1.8	14
54	SCA2 may present as levodopa-responsive parkinsonism. Movement Disorders, 2003, 18, 425-429.	3.9	99

#	Article	IF	Citations
55	Accurate Determination of Ataxin-2 Polyglutamine Expansion in Patients with Intermediate-Range Repeats. Genetic Testing and Molecular Biomarkers, 2002, 6, 217-220.	1.7	18
56	Independent Predictors of Cognitive Decline in Healthy Elderly Persons. Archives of Neurology, 2002, 59, 601.	4.5	300
57	Familial Aggregation of Parkinson Disease. Archives of Neurology, 2002, 59, 848-50.	4.5	75
58	Reply to correspondence from Inzelberg et al.??onset age of Parkinson disease?. American Journal of Medical Genetics Part A, 2002, 111, 461-461.	2.4	1
59	Expression of Î±-synuclein in the human brain: relation to Lewy body disease. Molecular Brain Research, 2001, 92, 58-65.	2.3	26
60	Frequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer Dementia. Archives of Neurology, 2001, 58, 383-7.	4.5	143
61	The Number of Trait Loci in Late-Onset Alzheimer Disease. American Journal of Human Genetics, 2000, 66, 196-204.	6.2	286
62	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. Neuroscience Letters, 1999, 260, 193-195.	2.1	27
63	Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's disease. Neuroscience Letters, 1999, 272, 140-142.	2.1	4
64	Apolipoprotein EÂÎµ4 Is Associated with Neuronal Loss in the Substantia nigra in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 1999, 10, 437-441.	1.5	8
65	Segregation analysis of Parkinson disease. , 1998, 80, 410-417.		19
66	Analysis of the Î±-synuclein G209A mutation in familial Parkinson's disease. Lancet, The, 1998, 351, 37-38.	13.7	55
67	Genetic Epidemiology of Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 1998, 11, 98-106.	2.3	38
68	Cognitive Markers Preceding Alzheimer's Dementia in the Healthy Oldest Old. Journal of the American Geriatrics Society, 1997, 45, 584-589.	2.6	172
69	Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Annals of Neurology, 1997, 42, 655-658.	5.3	52
70	Increased risk of Parkinson's disease in parents and siblings of patients. Annals of Neurology, 1994, 36, 659-661.	5.3	214
71	Lack of evidence for maternal effect in familial Alzheimer's disease. Genetic Epidemiology, 1993, 10, 461-464.	1.3	9